Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00813618 |
To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.
Condition | Intervention | Phase |
---|---|---|
Graft Versus Host Disease |
Drug: MEDI-507 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study |
Official Title: | Phase I Study of MEDI 507 in the Treatment of Pediatric Patients With at Least Grade II Acute Graft-Versus-Host Disease (GvHD) |
Enrollment: | 10 |
Study Start Date: | September 1999 |
Study Completion Date: | August 2004 |
Primary Completion Date: | June 2004 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
MEDI-507
|
Drug: MEDI-507
0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
|
2: Experimental
MEDI-507
|
Drug: MEDI-507
0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
|
3: Experimental
MEDI-507
|
Drug: MEDI-507
0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
|
This is a Phase I, open-label dose escalation trial of MEDI-507 in pediatric SCT and BMT recipients with at least Grade II acute GvHD. All patients will receive steroid therapy and MEDI-507 for treatment of GvHD
Ages Eligible for Study: | 2 Years to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Children's Hospital | |
Birmingham, Alabama, United States, 35233 | |
United States, California | |
Children's Hospital of Orange County | |
Orange, California, United States, 92868 | |
United States, Illinois | |
Children's Memorial Hospital | |
Chicago, Illinois, United States, 606014 | |
United States, Michigan | |
Univ. of Michigan Medical Center | |
Ann Arbor, Michigan, United States, 48109 | |
United States, New Jersey | |
Hackensack U. Medical Center | |
Hackensack, New Jersey, United States, 07601 | |
United States, Pennsylvania | |
The Children's Hosp. of Phila., Abramson Ped. Research Center | |
Philadelphia, Pennsylvania, United States, 19104 |
Responsible Party: | Medimmune LLC ( Christine A. Dingivan, MD ) |
Study ID Numbers: | MI-CP049 |
Study First Received: | December 19, 2008 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00813618 |
Health Authority: | United States: Food and Drug Administration |
Acute GvHD of at least Grade II severity |
Graft versus host disease Graft vs Host Disease Homologous wasting disease |
Immune System Diseases |